it'll likely be a good short into am strength tomorrow. Its only advisory panel recommendation, not FDA approval. it appears FDA have some major concerns given comments last week and stock had already run up leading up to this meeting. given the risk surrounding FDA decision and 150-200% overnight gains might be hard to digest.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.